--Agreement expands reach of industry-leading Horizon DXA system--
MARLBOROUGH, Mass.--(BUSINESS WIRE)--
Hologic, Inc. (Nasdaq: HOLX) announced today that it has signed an
agreement with DEXA+
to distribute Hologic’s Horizon® DXA system for body
composition measurement.
With over 20 years of experience, DEXA+ works with healthcare practices
nationwide to implement and optimize DXA technology to grow integrative
medicine, health and wellness programs. The partnership allows Hologic
to expand its expertise in body composition assessment and the reach of
its market-leading DXA system.
“This is a great partnership as we share a vision for, and commitment
to, DXA for comprehensive body composition assessment,” said Pete
Valenti, Hologic’s Division President, Breast and Skeletal Health
Solutions. “The combination of our industry-leading Horizon DXA system
with the deep expertise and reach of the DEXA+ channel will expand
patient access to this game-changing technology that can complement
wellness and training programs.”
Already considered the gold standard in bone densitometry technology,
DXA is increasingly being used for body composition assessment by both
collegiate and professional athletic programs, as well as training
centers across the country. The BodyLogic™ scan offered on Hologic’s
Horizon DXA system provides precise and in-depth measurements including
percent body fat, total lean mass, and limb comparison to detect muscle
imbalances.
Financial terms of the agreement were not disclosed.
For more information about Hologic’s Horizon DXA system and BodyLogic
scan, please visit DXAPerformance.com.
About Hologic
Hologic, Inc. is an innovative medical technology company primarily
focused on improving women's health and well-being through early
detection and treatment. For more information on Hologic, visit www.hologic.com.
Forward-Looking Statements
This news release may contain forward-looking information that involves
risks and uncertainties, including statements about the use of Hologic
products. There can be no assurance these products will achieve the
benefits described herein or that such benefits will be replicated in
any particular manner with respect to an individual patient, as the
actual effect of the use of the products can only be determined on a
case-by-case basis. In addition, there can be no assurance that these
products will be commercially successful or achieve any expected level
of sales. Hologic expressly disclaims any obligation or undertaking to
release publicly any updates or revisions to any such statements
presented herein to reflect any change in expectations or any change in
events, conditions or circumstances on which any such data or statements
are based.
Hologic, BodyLogic, Horizon and The Science of Sure are trademarks
and/or registered trademarks of Hologic, Inc., and/or its subsidiaries
in the United States and/or other countries.
SOURCE: Hologic, Inc.
View source version on businesswire.com:
https://www.businesswire.com/news/home/20190530005118/en/
Media Contact:
Jane Mazur
508.263.8764 (direct)
585.355.5978
(mobile)
[email protected]
Investor Contact:
Michael Watts
858.410.8588
[email protected]
Source: Hologic, Inc.